Oppenheimer Asset Management Inc. Ultragenyx Pharmaceutical Inc. Transaction History

Oppenheimer Asset Management Inc.

$8.04 Billion
Q3 2024

A detailed history of Oppenheimer Asset Management Inc. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 6,491 shares of RARE stock, worth $287,032. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,491

Previous 6,431 0.93%

Holding current value

$287,032

Previous $264,000 36.36%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$40.21 - $59.36 $2,412 - $3,561	60 Added 0.93%	6,491 $360,000
Q2 2024 Aug 08, 2024	BUY	$37.42 - $51.61 $4,191 - $5,780	112 Added 1.77%	6,431 $264,000
Q1 2024 May 06, 2024	BUY	$43.02 - $53.69 $860 - $1,073	20 Added 0.32%	6,319 $295,000
Q4 2023 Feb 13, 2024	SELL	$31.73 - $49.19 $26,113 - $40,483	-823 Reduced 11.56%	6,299 $301,000
Q3 2023 Nov 07, 2023	BUY	$34.92 - $46.66 $1,082 - $1,446	31 Added 0.44%	7,122 $253,000
Q2 2023 Aug 02, 2023	BUY	$37.35 - $52.15 $69,097 - $96,477	1,850 Added 35.3%	7,091 $327,000
Q1 2023 May 10, 2023	BUY	$36.99 - $48.71 $3,994 - $5,260	108 Added 2.1%	5,241 $210,000
Q4 2022 Feb 06, 2023	BUY	$33.72 - $46.33 $173,084 - $237,811	5,133 New	5,133 $237,000
Q2 2022 Aug 08, 2022	SELL	$45.8 - $85.4 $31,876 - $59,438	-696 Reduced 16.74%	3,462 $206,000
Q1 2022 May 12, 2022	BUY	$62.2 - $84.4 $34,023 - $46,166	547 Added 15.15%	4,158 $302,000
Q4 2021 Feb 02, 2022	SELL	$73.71 - $87.86 $6,781 - $8,083	-92 Reduced 2.48%	3,611 $304,000
Q3 2021 Nov 12, 2021	BUY	$77.92 - $102.4 $288,537 - $379,187	3,703 New	3,703 $334,000
Q2 2021 Aug 03, 2021	SELL	$92.19 - $115.71 $168,984 - $212,096	-1,833 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$106.9 - $167.73 $71,088 - $111,540	-665 Reduced 26.62%	1,833 $209,000
Q4 2020 Feb 11, 2021	SELL	$84.4 - $177.39 $61,443 - $129,139	-728 Reduced 22.57%	2,498 $346,000
Q3 2020 Nov 13, 2020	BUY	$72.98 - $90.0 $235,433 - $290,340	3,226 New	3,226 $265,000
Q2 2020 Aug 11, 2020	SELL	$46.91 - $78.22 $105,453 - $175,838	-2,248 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$33.8 - $62.9 $49,719 - $92,525	1,471 Added 189.32%	2,248 $100,000
Q4 2019 Feb 07, 2020	BUY	$36.08 - $45.83 $2,092 - $2,658	58 Added 8.07%	777 $33,000
Q3 2019 Oct 31, 2019	BUY	$42.5 - $63.11 $765 - $1,135	18 Added 2.57%	719 $31,000
Q2 2019 Aug 09, 2019	SELL	$54.93 - $74.36 $19,719 - $26,695	-359 Reduced 33.87%	701 $45,000
Q1 2019 Apr 24, 2019	SELL	$39.87 - $69.36 $7,854 - $13,663	-197 Reduced 15.67%	1,060 $74,000
Q4 2018 Jan 30, 2019	BUY	$38.89 - $77.3 $48,884 - $97,166	1,257 New	1,257 $55,000
Q4 2017 Feb 07, 2018	SELL	$43.54 - $57.32 $16,632 - $21,896	-382 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$49.79 - $66.32 $19,019 - $25,334	382	382 $20,000

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.6M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.1B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.

Account

Oppenheimer Asset Management Inc. Ultragenyx Pharmaceutical Inc. Transaction History